Rendering

Component: (Network and Table)
Network
31403 - Disclosure - Income Taxes (Tables)
(http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001597264 (http://www.sec.gov/CIK)
Income TaxesPeriod [Axis]
2016-01-01 - 2016-12-31
Income Taxes
 
Schedule of the reconciliation of the effective tax rate

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31,

 

 

 

2016

    

2015

 

2014

 

Federal income tax (benefit) at statutory rate

    
34.00

%  
34.00

%  
34.00

%

Permanent differences

 
(2.74)

 
(3.30)

 
(1.87)

 

Federal research and development credits

 
1.02

 
1.09

 
1.3

 

Federal orphan drug credits

 
6.63

 
0.55

 

 —

 

State income tax, net of federal benefit

 
4.81

 
4.72

 
4.93

 

Other

 
(0.78)

 
0.56

 
0.7

 

Change in valuation allowance

 
(42.94)

 
(37.62)

 
(39.06)

 

Effective income tax rate

 

 —

%

 —

%

 —

%

 

  
Schedule of the deferred tax assets and liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

 

2016

 

2015

 

2014

 

Deferred tax assets:

    

 

 

    

 

 

 

 

 

 

Net operating loss carryforwards

 

$
69,443

 

$
48,291

 

$
30,603

 

Research and development credit carryforwards

 

 
3,833

 

 
2,829

 

 
1,949

 

Orphan drug credit carryforwards

 

 
5,095

 

 
289

 

 

 —

 

Accrued expenses and other

 

 
2,914

 

 
1,374

 

 
628

 

Deferred revenue

 

 
2,627

 

 

 —

 

 

 —

 

Deferred lease incentive

 

 
1,324

 

 
1,551

 

 

 —

 

Deferred rent

 

 
366

 

 
331

 

 
54

 

Total gross deferred tax asset

 

 
85,602

 

 
54,665

 

 
33,234

 

Deferred tax liability

 

 
(1,535)

 

 
(1,702)

 

 
(85)

 

Debt discount

 

 
(14)

 

 
(39)

 

 
(74)

 

Valuation allowance

 

 
(84,053)

 

 
(52,924)

 

 
(33,075)

 

Net deferred tax asset

 

$

 —

 

$

 —

 

$

—